Referencia número: HY-14805A

Tecovirimat monohydrate

(Synonyms: ST-246 monohydrate)

3 Cited Publications

Revisión del cliente

Based on 3 publication(s) in Google Scholar

Tecovirimat (ST-246) monohydrate is the monohydrate form of Tecovirimat (HY-14805). Tecovirimat monohydrate is an orally bioavailable and selective compound against orthopoxviruses [including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), smallpox and variola viruses]. Tecovirimat monohydrate is evaluated against vaccinia, cowpox virus, ectromelia virus with EC₅₀ values of 0.01 μM, 0.48 μM and 0.05 μM, respectively. Tecovirimat monohydrate targets the orthopoxvirus protein VP37 which is necessary for membrane envelopment of intracellular mature virus particles to form enveloped virus. Tecovirimat monohydrate exerts antiviral activity on the target of the cowpox virus V061 gene, which is homologous to vaccinia virus F13L, encoding a major envelope protein (p37) required for production of extracellular virus. Tecovirimat monohydrate could be used in the study for orthopoxvirus-induced diseases.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 97.35%
No. CAS: 1162664-19-8
Fòrmula: C₁₉H₁₇F₃N₂O₄
Peso molecular:394.34

Almacenamiento:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Tecovirimat monohydrate Chemical Structure

No. CAS: 1162664-19-8

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- In Vitro
- In Vivo
- Ensayo clínico
Chemical Information
Publications (3)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

In Vitro

Tecovirimat monohydrate (0-50 μM, 3 days) is a potent and specific inhibitor of orthopoxvirus replication that is active against a broad spectrum of orthopoxviruses^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

Vero cells
Concentration:

0-50 μM
Incubation Time:

3 days
Result:

Was more potent relative to Cidofovir (CDV) (HY-17438) after vaccinia virus strain NYCBH infection in cytopathic effect (CPE)-based assays in vero cells.

In Vivo

Tecovirimat monohydrate (50 mg/kg, oral gavage, twice a day for 14 days) mounts a protective immune response to vaccinia virus infection in a lethal intranasal vaccinia virus challenge model of mice^[1].
Tecovirimat monohydrate (50 mg/kg, oral gavage, 5 days) can inhibit vaccinia virus-induced lesion formation following i.v. viral inoculation in Vaccinia virus-mouse tail lesion model^[1].
Tecovirimat monohydrate (100 mg/kg, p.o., daily for various durations of 5, 7, 10, or 14 days) significantly decreases in mortality of cowpox virus (CV)-infected mice^[2].

Pharmacokinetic parameters of ST-246 in mice^[1]

Dosage (mg/kg)	T_max (h)	C_max (μg/mL)	AUC_0-t (μg·h/mL)	T_1/2 (h)
30	2.7	32.5	284.2	2.5
100	1.0	62.2	287.6	2.5

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Weanling BALB/c mice challenged with vaccinia virus strain(4 to 6 weeks of age and weighing 15 to 20 g)^[1]
Dosage:

50 mg/kg
Administration:

oral gavage, twice a day for 14 days
Result:

Tecovirimat monohydrate-treated mice mounted a protective immune response to vaccinia virus infection in a lethal intranasal vaccinia virus challenge model.

Animal Model:

NMRI mice inoculated via the tail vein with vaccinia virus(4 to 6 weeks of age and weighing 15 to 20 g)^[1]
Dosage:

50 mg/kg
Administration:

oral gavage, 5 days
Result:

Showed a dose-dependent reduction in the numbers of tail lesions at day 8 postinfection relative to placebo-treated control animals in mice.

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 1162664-19-8
Appearance Solid
Peso molecular 394.34
Fòrmula C₁₉H₁₇F₃N₂O₄
Color White to off-white
SMILES

O=C(NN(C([C@]1([H])[C@@]2([H])[C@@](C3)([H])[C@@]3([H])[C@@](C=C2)([H])[C@]41[H])=O)C4=O)C5=CC=C(C(F)(F)F)C=C5.O
Synonyms

ST-246 monohydrate
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (3)

All Microbiological Assay

Sort by:

Journal Impact Factor

BMC Microbiol

Pathogenic signatures and therapeutic evaluation of emergent MPXV Clade Ib in low-susceptibility and immunocompromised mouse models. [Abstract]

2026 Jun 9. PMID: 42260341
Antiviral Res

Salinomycin inhibits orthopoxvirus infection in vitro and in vivo by blocking endosomal acidification. [Abstract]

2026 May:249:106403. PMID: 41941992
Biosaf Health

2025 Jan 5.

Tecovirimat monohydrate purchased from MedChemExpress. Usage Cited in: Biosaf Health. 2025 Jan 5.

Inhibition of EEV by ST-246 (Tecovirimat). HeLa cells were infected with VACV WR at a MOI of 3 for 2 h and then added increased dosages of ST-246 for another 22 h. The EEV was collected and titrated by BSC-1 cells.

Solvente y solubilidad

In Vitro:

DMSO : 100 mg/mL (253.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5359 mL

12.6794 mL

25.3588 mL

5 mM

0.5072 mL

2.5359 mL

5.0718 mL

10 mM

0.2536 mL

1.2679 mL

2.5359 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (281 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Quenelle DC, et al. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice[J]. Antimicrob Agents Chemother. 2007 Feb;51(2):689-95. [Content Brief]

[2]. DeLaurentis CE, et al. New Perspectives on Antimicrobial Agents: Tecovirimat monohydrate for Treatment of Human Monkeypox Virus[J]. Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0122622. [Content Brief]

[3]. Yang G, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge[J]. J Virol. 2005 Oct;79(20):13139-49. [Content Brief]

[4]. Russo AT, et al. An overview of Tecovirimat monohydrate for smallpox treatment and expanded anti-orthopoxvirus applications[J]. Expert Rev Anti Infect Ther. 2021 Mar;19(3):331-344. [Content Brief]

[5]. TYAVANAGIMATT SR, et al., Rehydration of micronized tecovirimat monohydrate. WO2015077143.

[6]. Almehmadi M, et al. A Glance at the Development and Patent Literature of Tecovirimat monohydrate: The First-in-Class Therapy for Emerging Monkeypox Outbreak[J]. Viruses. 2022 Aug 25;14(9):1870. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5359 mL	12.6794 mL	25.3588 mL	63.3971 mL
	5 mM	0.5072 mL	2.5359 mL	5.0718 mL	12.6794 mL
	10 mM	0.2536 mL	1.2679 mL	2.5359 mL	6.3397 mL
	15 mM	0.1691 mL	0.8453 mL	1.6906 mL	4.2265 mL
	20 mM	0.1268 mL	0.6340 mL	1.2679 mL	3.1699 mL
	25 mM	0.1014 mL	0.5072 mL	1.0144 mL	2.5359 mL
	30 mM	0.0845 mL	0.4226 mL	0.8453 mL	2.1132 mL
	40 mM	0.0634 mL	0.3170 mL	0.6340 mL	1.5849 mL
	50 mM	0.0507 mL	0.2536 mL	0.5072 mL	1.2679 mL
	60 mM	0.0423 mL	0.2113 mL	0.4226 mL	1.0566 mL
	80 mM	0.0317 mL	0.1585 mL	0.3170 mL	0.7925 mL
	100 mM	0.0254 mL	0.1268 mL	0.2536 mL	0.6340 mL

Keywords

Tecovirimat monohydrate

3 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Tecovirimat monohydrate

Publications Citing Use of MedChemExpress (MCE) Tecovirimat monohydrate

Actividad biológica

Chemical Information

Publications (3)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Tecovirimat monohydrate Related Classifications

HY-14805A Related Classifications